Being PRO-ACTive: A Collaborative Effort to Bring Big Data to ALS. Alex Sherman, Melanie Leitner, Prize4Life

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Being PRO-ACTive: A Collaborative Effort to Bring Big Data to ALS. Alex Sherman, Melanie Leitner, Prize4Life"

Transcription

1 Being PRO-ACTive: A Collaborative Effort to Bring Big Data to ALS Alex Sherman, Melanie Leitner, Prize4Life

2 What is ALS (Lou Gehrig s Disease)? Orphan disease 100% lethal within 2-5 years from diagnosis (respiratory failure) Only existing FDA-approved treatment prolongs life by 2-3 months Affects both men and women and can strike at any adult age Expensive disease costing $ ,000/year in direct costs Avi ~ 9 months post-diagnosis Avi ~3 years post-diagnosis

3 The Goals of the PRO-ACT Project PRO-ACT = Pooled Resource Open-Access ALS Clinical Trials Database To obtain subject records from completed Phase II/III ALS clinical trials; Clean, harmonize, aggregate and anonymize data; Make the anonymized dataset available to the global R&D community to: Enable scientists and clinicians to learn more about the disease; Increase the likelihood of success of ALS clinical trials; Reduce the cost required to determine drug effectiveness

4 Who Are Our partnersforcures?

5 Prize4Life Prize4Life is an innovative, results-oriented 501(c)(3) not-for-profit organization focusing exclusively on Amyotrophic Lateral Sclerosis (ALS) Our mission is to accelerate the discovery of treatments and a cure for ALS by using powerful incentives to attract new people and drive innovation. Prize4Life has embraced the Incentive Prize Model as part of its portfolio of strategies to change the landscape for ALS research In addition, Prize4Life has focused on high-impact research infrastructure projects designed to enhance and accelerate translational efforts

6 Who Are Our partnersforcures?

7 NCRI s mission is to accelerate translational research in neurological disorders by: Mapping the clinical development of potential therapies; Custom design of clinical research protocols; Establishing and managing disease-specific research consortia (NEALS, ALD Connect); Designing, deploying and managing registries, repositories and biobanks; Providing resources, staff, and services to conduct clinical trials and research; Fostering and empowering scientific collaboration; Educating and mentoring future leaders in the field of clinical research; NCRI also serves as: Clinical Coordinating Center for NeuroNEXT, a NIH-supported network for phase II clinical trials in neurology; Data Coordinating Center (DCC) for the NIH-funded Specialized Programs of Translational Research in Acute Stroke (SPOTRIAS); DCC for the Rapidly-Acting Treatments for Treatment-Resistant Depression (RAPID) network; ACRO for 20+ clinical trials and studies in CNS diseases.

8 Who Are Our partnersforcures?

9 PRO-ACT Timeline Proposal Funding 2011 Data sources identification 2011 Legal agreement 2011 Getting the data 2011 Platform development Data Cleaning Harmonization Anonymization Import Launch Dec Analyses & crowdsourcing NOW!

10 Data Workflow Define Common Data Structure (CDS) Analyze individual datasets Map elements from individual datasets to CDS elements Import Data Analyze/Crowdsource

11 PRO-ACT Platform

12 Over 180 requests from 21 countries PRO-ACT Users 64% -PhD/MD 13 pharma companies 14 informatics companies 58+ academic institutions 3 government entities

13 Impacts of PRO-ACT on ALS R&D CONFIDENTIAL Scientific Benefits: Understanding of natural history and disease heterogeneity Novel biomarkers and pathways of disease Clinical Development Benefits Simulations Test stratification theories Reduce the cost of future ALS clinical trials Explore link between disease progression and medication use Other Benefits Grow quantitative workforce with interest in/exposure to ALS data

14 The ALS Prediction Prize: An Early Effort to Translate Big Data into Health

15 The ALS Prediction Prize: A Case Study for Big Data To bring attention to PRO-ACT and to ALS from quantitative communities worldwide we launched an incentive prize: Project Rational: There is currently no effective mechanism to predict ALS progression so as to be able to stratify rapid and slow ALS progressors Enabling earlier and more reliable prediction: would improve clinical trials by helping to account for heterogeneity within the ALS population (less variability fewer patients needed easier, less expensive more interpretable clinical trials effective treatment faster) could improve clinical practice in ALS by enabling earlier use of palliatives and better life-planning by patients and their families

16 The ALS Prediction Prize: A Case Study for Big Data Project Implementation: Approach: We launched a $25,000 prize for the best prediction algorithm(s) that could take 3 months of patient clinical data and use this to predict the progression of a given patient s disease over the following 9 months Timeline: 3 months for competitors to develop and test algorithms Partners: The DREAM Project, Innocentive, NCRI, The Bowen Family, and brilliant quantitative minds around the world

17 The ALS Prediction Prize: A Case Study for Big Data Teams Around the World Competed for the Prize: 1073 solvers from 64 countries

18 The ALS Prediction Prize: A Case Study for Big Data Results: 37 unique algorithm solutions submitted $50K in prizes awarded New tools (currently being tested by companies) Modeling suggests use of the algorithms would reduce the number of patients needed to see a treatment effect by 23% in clinical trials Multiple novel predictors identified The ALS Prediction Prize program generated several high quality algorithms with the potential to assess ALS progression sooner and more reliably than current clinical practice

19 PRO-ACT Future Identify and solicit more data from clinical trials, both industry and academic (> 10 datasets are identified for their inclusion into PRO ACT in the nearest future); Secure funding for data aggregation and for maintenance and support of the platform and infrastructure; Provide data analytical services to the research community; Ensure visibility of PRO ACT resource through an outreach program; Create another challenge to attract researchers outside ALS and even medical communities; Prove feasibility of a crowdsourcing model for medical discoveries in rare diseases; Expand platform s utilization and know how to other diseases.

20 Importance of PRO-ACT Project The PRO-ACT platform is a resource available to the clinical research community through the efforts of a unique partnership among nonprofits, academic centers, and industry; By sharing and pooling data you can answer new questions and gain new insights into diseases, especially rare ones; Crowdsourcing is a great way to expand the pool of innovative thinkers and approaches available to address a difficult problem; If you are thinking of building a clinical database or running an incentive prize in your disease of interest, Prize4Life and NCRI can help!

21 PRO-ACT Collaboration Score (p4c) Academia Non-profit Charity Industry PEOPLE Academia Non-profit Charity Industry PEOPLE

22 partnersforcures Prize4Life Avi Kremer, CEO Shen Bennett Jessica Goodman, PhD Thomas Leavitt Melanie Leitner, PhD Guadalupe Martinez Neta Zach, PhD ALS Prediction Prize Collaboration Rebecca Betensky, PhD (HSPH) Robert Kueffner, PhD (DREAM) Raquel Norel, PhD (DREAM) Gustavo Stolivitsky (DREAM) Orla Hardiman, MD (Dublin) NEALS/NCRI Merit Cudkowicz, MD Nazem Atassi, MD James Berry, MD Igor Katsovskiy David Schoenfeld, PhD Alex Sherman Amy Shui Ervin Sinani Jason Walker With funding from the

23 BE YOURS. THANK YOU PRO-ACT can be found at:

Being PRO-ACTive - Can Big Data Mean Big Solutions of Rare Diseases? Presentation by Neta Zach, PhD Chief Scientific Officer

Being PRO-ACTive - Can Big Data Mean Big Solutions of Rare Diseases? Presentation by Neta Zach, PhD Chief Scientific Officer Being PRO-ACTive - Can Big Data Mean Big Solutions of Rare Diseases? Presentation by Neta Zach, PhD Chief Scientific Officer 1 Who we are Big data and rare disease Case study: The PRO-ACT Database Case

More information

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet

TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet Dalvir Gill, PhD - Chief Executive Officer 17 October, 2014 Presentation Objectives + TransCelerate History + Participating

More information

Unlock Your Global Business Potential: Supporting Life Sciences in the UK

Unlock Your Global Business Potential: Supporting Life Sciences in the UK Unlock Your Global Business Potential: Supporting Life Sciences in the UK Dr Mark Treherne, Chief Executive, Life Science Investment Organisation Health Research Authority 31 st March, 2014 THE UK HAS

More information

How FDA Promotes Partnerships to Accelerate Medical Product Development

How FDA Promotes Partnerships to Accelerate Medical Product Development How FDA Promotes Partnerships to Accelerate Medical Product Development ShaAvhrée Buckman-Garner, MD, PhD Director, Office of Translational Sciences Center for Drug Evaluation and Research Food and Drug

More information

What s Next for Data Sharing: Insight from the NIH Experience

What s Next for Data Sharing: Insight from the NIH Experience What s Next for Data Sharing: Insight from the NIH Experience Jerry Sheehan Assistant Director for Policy Development National Library of Medicine National Institutes of Health SHARE In-Person Meeting

More information

The registry of the future: Leveraging EHR and patient data to drive better outcomes

The registry of the future: Leveraging EHR and patient data to drive better outcomes The registry of the future: Leveraging EHR and patient data to drive better outcomes Brian J. Kelly, M.D. President, Payer and Provider Solutions, Quintiles Jason Colquitt, VP, IT, Head of RWLPR IT, Global

More information

CLINICAL DEVELOPMENT OPTIMIZATION

CLINICAL DEVELOPMENT OPTIMIZATION PAREXEL CLINICAL RESEARCH SERVICES CLINICAL DEVELOPMENT OPTIMIZATION Enhancing the clinical development process to achieve optimal results ADVANCED TECHNOLOGY COMBINED WITH INTELLIGENT THINKING CAN HELP

More information

Visualizing the Future of MS Research: ACP s Repository Holds the Map

Visualizing the Future of MS Research: ACP s Repository Holds the Map Dear Friends, This issue is all about Big Data to Knowledge, otherwise known as BD2K. This refers to society s growing ability to gather a wealth of information about people in our case, people with MS

More information

The Evolution of Data Platforms in IMI. Anthony Rowe, Janssen R&D IT 08 April 2016 Med-e-Tel Luxembourg

The Evolution of Data Platforms in IMI. Anthony Rowe, Janssen R&D IT 08 April 2016 Med-e-Tel Luxembourg The Evolution of Data Platforms in IMI Anthony Rowe, Janssen R&D IT 08 April 2016 Med-e-Tel Luxembourg Three trends in technology today Ubiquity of the Internet Three trends in technology today Ubiquity

More information

The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder

The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases Scott Johnson CEO, President and Founder Introduction Broken system of medical research No fault, system

More information

Big Data and Big Privacy in Brain Disorder Research: Changing the System OECD 2013 Donald T. Stuss, PhD, President and Scientific Director

Big Data and Big Privacy in Brain Disorder Research: Changing the System OECD 2013 Donald T. Stuss, PhD, President and Scientific Director Big Data and Big Privacy in Brain Disorder Research: Changing the System OECD 2013 Donald T. Stuss, PhD, President and Scientific Director Ontario Brain Institute June 3, 2013 THEME Gathering big data

More information

How can you unlock the value in real-world data? A novel approach to predictive analytics could make the difference.

How can you unlock the value in real-world data? A novel approach to predictive analytics could make the difference. How can you unlock the value in real-world data? A novel approach to predictive analytics could make the difference. What if you could diagnose patients sooner, start treatment earlier, and prevent symptoms

More information

2016 Call for Projects on ALS Research

2016 Call for Projects on ALS Research 2016 Call for Projects on ALS Research 2016 AriSLA Call for Research Projects: PROMOTING RESEARCH EXCELLENCE IN THE FIGHT AGAINST ALS Deadline: at 1.00 pm, March 17 th 2016 1. Aims of the 2016 AriSLA Call

More information

The Clinical Trials Process an educated patient s guide

The Clinical Trials Process an educated patient s guide The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-

More information

Anne B. Young, MD, PhD, Neuroscience Translational Medicine Fellowship. Unique fellowships, endless opportunities

Anne B. Young, MD, PhD, Neuroscience Translational Medicine Fellowship. Unique fellowships, endless opportunities Anne B. Young, MD, PhD, Neuroscience Translational Medicine Fellowship Unique fellowships, endless opportunities The Anne B. Young Neuroscience Translational Medicine Fellowship Biogen Idec, in collaboration

More information

2011-2016 Strategic Plan. Creating a healthier world through bold innovation

2011-2016 Strategic Plan. Creating a healthier world through bold innovation 2011-2016 Strategic Plan Creating a healthier world through bold innovation 2011-2016 STRATEGIC PLAN Table of contents I. Global direction 1 Mission and vision statements 2 Guiding principles 3 Organizational

More information

UNCLASSIFIED STATEMENT BY

UNCLASSIFIED STATEMENT BY UNCLASSIFIED FINAL STATEMENT BY CAROLYN J.M. BEST, PhD PROGRAM MANAGER OF THE PROSTATE CANCER RESEARCH PROGRAM OF THE CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS OF THE UNITED STATES ARMY MEDICAL

More information

The National Center for Advancing Translational Sciences

The National Center for Advancing Translational Sciences The National Center for Advancing Translational Sciences The Clinical and Translational Science Award Program in the Division of Clinical Innovation CHRISTOPHER AUSTIN, M.D. DIRECTOR, NCATS PETRA KAUFMANN,

More information

cystic fibrosis (CF) in the United States, we are pleased to submit the following testimony to the

cystic fibrosis (CF) in the United States, we are pleased to submit the following testimony to the Robert J. Beall, Ph.D. Cystic Fibrosis Foundation President and Chief Executive Officer On behalf of the Cystic Fibrosis Foundation and the approximately 30,000 people with cystic fibrosis (CF) in the

More information

Precision Medicine Challenge Centralized Pharmacogenomic Recruitment Database

Precision Medicine Challenge Centralized Pharmacogenomic Recruitment Database Precision Medicine Challenge Centralized Pharmacogenomic Recruitment Database March 13, 2016 Table of Contents Key Proposal Elements Strategic Considerations Page 2 Key Proposal Elements Current Trial

More information

New strategies in the field of rare diseases: a comprehensive international approach Runolfur Palsson

New strategies in the field of rare diseases: a comprehensive international approach Runolfur Palsson 17 January 2012 Annual Conference of the Icelandic Medical Association New strategies in the field of rare diseases: a comprehensive international approach Runolfur Palsson Rare diseases In Europe, a disease

More information

Transforming relationships Unleashing innovation

Transforming relationships Unleashing innovation Transforming relationships Unleashing innovation Translating Discoveries Into Products A model for innovation driven economic growth Barbara Handelin, PhD 1 The Innovation Gap Economic Opportunity Industries

More information

Strategic Consulting Services

Strategic Consulting Services Services 1 Leadership Team Mark Levonyak President mlevonyak@davaonc.com Mobile: 214.460.5051 Martin W. Lee, MD EVP, Clinical Trial Services mlee@davaonc.com Mobile: 952.373.1405 John Eckardt, MD Chief

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

EURORDIS-NORD-CORD Joint Declaration of. 10 Key Principles for. Rare Disease Patient Registries

EURORDIS-NORD-CORD Joint Declaration of. 10 Key Principles for. Rare Disease Patient Registries EURORDIS-NORD-CORD Joint Declaration of 10 Key Principles for Rare Disease Patient Registries 1. Patient Registries should be recognised as a global priority in the field of Rare Diseases. 2. Rare Disease

More information

From IMI to IMI2. Hugh Laverty PROTECT London

From IMI to IMI2. Hugh Laverty PROTECT London From IMI to IMI2 Hugh Laverty 20.02.2015 PROTECT London Innovative Medicines Initiative: Joining forces in the healthcare sector The biggest public/private partnership in Life Science aiming to: Make drug

More information

J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S

J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S PURPOSE JDRF, the world s leading non-profit organization with

More information

Principles for Responsible Clinical Trial Data Sharing

Principles for Responsible Clinical Trial Data Sharing Principles for Responsible Clinical Trial Data Sharing Our Commitment to Patients and Researchers Biopharmaceutical companies are committed to enhancing public health through responsible sharing of clinical

More information

Project Management. Dissemination and Exploitation Services in Horizon 2020

Project Management. Dissemination and Exploitation Services in Horizon 2020 Project Management Dissemination and Exploitation Services in Horizon 2020 Ontwerp: Studio Edwin de Boer 2 Project Management Dissemination and Exploitation Services in Horizon 2020 ttopstart - Project

More information

TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials

TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials Pharmaceutical leader deploys TIBCO Spotfire enterprise analytics platform across its drug discovery organization

More information

Policy Based Pull Incentives for Creating Breakthrough CNS Drugs

Policy Based Pull Incentives for Creating Breakthrough CNS Drugs Policy Based Pull Incentives for Creating Breakthrough CNS Drugs Jan 20, 2015 Financial Incentives Workshop Neuroscience Forum, IOM Washington, DC Dennis W. Choi, MD, PhD SUNY Stony Brook Key Assumptions

More information

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this

More information

Fiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements

Fiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements Fiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) Reference Table of Award Mechanisms and Submission Requirements PCRP AWARD MECHANISMS WITH EMPHASIS ON RESOURCES Clinical Consortium Award

More information

Using Big Data to Advance Healthcare Gregory J. Moore MD, PhD February 4, 2014

Using Big Data to Advance Healthcare Gregory J. Moore MD, PhD February 4, 2014 Using Big Data to Advance Healthcare Gregory J. Moore MD, PhD February 4, 2014 Sequencing Technology - Hype Cycle (Gartner) Gartner - Hype Cycle for Healthcare Provider Applications, Analytics and Systems,

More information

Transforming study start-up for optimal results

Transforming study start-up for optimal results Insight brief Transforming study start-up for optimal results A holistic, data-driven approach integrating technology, insights and proven processes to position clinical trials for ultimate success Up

More information

Using Predictive Analytics to Reduce COPD Readmissions

Using Predictive Analytics to Reduce COPD Readmissions Using Predictive Analytics to Reduce COPD Readmissions Agenda Information about PinnacleHealth Today s Environment PinnacleHealth Case Study Questions? PinnacleHealth System Non-profit, community teaching

More information

The new strategic approach to better medicines in IMI2 Example Diabetes Mellitus

The new strategic approach to better medicines in IMI2 Example Diabetes Mellitus The new strategic approach to better medicines in IMI2 Example Diabetes Mellitus Bernd Stowasser, PhD, MS, Associate Vice President, Head of European Public Private Partnerships Office Sanofi R&D Strategy,

More information

Opportunities for advancing biomarkers for patient stratification and early diagnosis in liver disease

Opportunities for advancing biomarkers for patient stratification and early diagnosis in liver disease Opportunities for advancing biomarkers for patient stratification and early diagnosis in liver disease 80 Liver Disease and Obesity Liver disease biomarkers: Percent of adult population (United States)

More information

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles J.P. Morgan 2016 Healthcare Conference Tom Pike CEO January 12, 2016 Copyright 2016 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking

More information

TRANSFORMING LIFE SCIENCES THROUGH ENTERPRISE ANALYTICS

TRANSFORMING LIFE SCIENCES THROUGH ENTERPRISE ANALYTICS TRANSFORMING LIFE SCIENCES THROUGH ENTERPRISE HOW SOLUTIONS AND ENTERPRISE ENVIRONMENTS ARE IMPROVING EFFICIENCY AND ENABLING NEW INSIGHTS THROUGHOUT THE LIFE SCIENCES INDUSTRY Matt Gross Director Health

More information

2016 Cure SMA Research Update Jill Jarecki, PhD June 18, 2016

2016 Cure SMA Research Update Jill Jarecki, PhD June 18, 2016 2016 Cure SMA Research Update Jill Jarecki, PhD June 18, 2016 2016 Research Update Session Presentation on Cure SMA Research Activities Jill Jarecki PhD, Cure SMA Research Director - 15 min Talks and Question

More information

FROM MOLECULES TO MEDICINE: HOW ARE NEW DRUGS & THERAPIES DEVELOPED?

FROM MOLECULES TO MEDICINE: HOW ARE NEW DRUGS & THERAPIES DEVELOPED? FROM MOLECULES TO MEDICINE: HOW ARE NEW DRUGS & THERAPIES DEVELOPED? FROM MOLECULES TO MEDICINE: HOW ARE NEW DRUGS & THERAPIES DEVELOPED? Introduction This Global Genes Toolkit will provide you with an

More information

Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management

Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management Written Notice of Participation by the Clinical Data Interchange Standards Consortium (CDISC) and Written Statement for Discussion Topics to be Addressed In the FDA Public Hearing: Electronic Submission

More information

Re: Public Access to Peer-Reviewed Scholarly Publications Resulting from Federally Funded Research Request for Information

Re: Public Access to Peer-Reviewed Scholarly Publications Resulting from Federally Funded Research Request for Information December 19, 2011 Office of Science and Technology Policy National Science and Technology Council s Task Force on Public Access to Scholarly Publications 725 17 th Street Washington DC 20502 Via Email

More information

The CTSA Program: Collaborative Innovation for Translational Research

The CTSA Program: Collaborative Innovation for Translational Research The CTSA Program: Collaborative Innovation for Translational Research Petra Kaufmann, MD, MSc Director, Division of Clinical Innovation NCATS ADVISORY COUNCIL MEETING JUNE 18, 2015 Transforming the CTSA

More information

Orphan Pharma: pathfinders for an increasingly specialised industry

Orphan Pharma: pathfinders for an increasingly specialised industry Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty

More information

A Glimpse at the Future of Predictive Analytics in Healthcare

A Glimpse at the Future of Predictive Analytics in Healthcare A Glimpse at the Future of Predictive Analytics in Healthcare 1 Dr. Thomas Hill Dell Executive Director, Analytics Dell Software Group Tom.Hill@software.dell.com www.linkedin.com/in/drthomashill @DrTomHill

More information

Image Standardization and Interpretation Issues The NCI Perspective

Image Standardization and Interpretation Issues The NCI Perspective Image Standardization and Interpretation Issues The NCI Perspective Lalitha K. Shankar, MD, PhD, Acting Chief, Clinical Trials Branch Cancer Imaging Program National Cancer Institute April 2010 Imaging

More information

ERA-Net COFUND Research Programmes on Rare Diseases (E-RARE)

ERA-Net COFUND Research Programmes on Rare Diseases (E-RARE) Bologna 15 Dicembre 2014 ERA-Net COFUND Research Programmes on Rare Diseases (E-RARE) The Role of RER-ASSR Antonio Addis Research Governance Area Agenzia Sanitaria e Sociale Regionale How do Regions might

More information

ORPHAN DRUG. ORPHAN DRUG & RARE DISEASE DEVELOPMENT: Understanding the U.S. and European Regulatory Landscape & RARE DISEASE DEVELOPMENT

ORPHAN DRUG. ORPHAN DRUG & RARE DISEASE DEVELOPMENT: Understanding the U.S. and European Regulatory Landscape & RARE DISEASE DEVELOPMENT : Abstract Today, more than ever, researchers are focused on providing care for the approximately 7,000 rare diseases that may have been overlooked in the past due to the challenges of conducting clinical

More information

MULTIPLE SCLEROSIS PHYSICIAN RESOURCES

MULTIPLE SCLEROSIS PHYSICIAN RESOURCES MULTIPLE SCLEROSIS PHYSICIAN RESOURCES This resource provides internet links that may be of interest to your patients diagnosed with multiple sclerosis. Many of these links will provide invaluable information

More information

P4 Medicine: Personalized, Predictive, Preventive, Participatory A Change of View that Changes Everything

P4 Medicine: Personalized, Predictive, Preventive, Participatory A Change of View that Changes Everything P4 Medicine: Personalized, Predictive, Preventive, Participatory A Change of View that Changes Everything Leroy E. Hood Institute for Systems Biology David J. Galas Battelle Memorial Institute Version

More information

Participating in Alzheimer s Disease Clinical Trials and Studies

Participating in Alzheimer s Disease Clinical Trials and Studies Participating in Alzheimer s Disease Clinical Trials and Studies FACT SHEET When Margaret was diagnosed with earlystage Alzheimer s disease at age 68, she wanted to do everything possible to combat the

More information

A New MS Consortium for A New MS Clinical Outcome Measure

A New MS Consortium for A New MS Clinical Outcome Measure A New MS Consortium for A New MS Clinical Outcome Measure Nicholas G. LaRocca, Ph.D. Richard Rudick, M.D. Lynn Hudson, Ph.D. Co-Directors, MSOAC American Academy of Neurology March 20 th, 2013 The problem

More information

Telehealth Solutions Enhance Health Outcomes and Reduce Healthcare Costs

Telehealth Solutions Enhance Health Outcomes and Reduce Healthcare Costs Text for a pull out can go heretext for a pull out can go heretext for a pull out can go Text for a pull out can go here Text for a pull out can go here Telehealth Solutions Enhance Health Outcomes and

More information

Hacking Brain Disease for a Cure

Hacking Brain Disease for a Cure Hacking Brain Disease for a Cure Magali Haas, CEO & Founder #P4C2014 Innovator Presentation 2 Brain Disease is Personal The Reasons We Fail in CNS Major challenges hindering CNS drug development include:

More information

EHR4CR ENABLING PROACTIVE RESEARCH

EHR4CR ENABLING PROACTIVE RESEARCH EHR4CR ENABLING PROACTIVE RESEARCH Neelam Patel Neelam Consulting Electronic Health Records for Clinical Research 76 Why change how I currently operate? To more visible to the clinical trial community

More information

Afprøvning af medicin på sjældne områder: hvad er udfordringerne. Dr. Peter Høngaard Andersen, CEO, Innovation Fund Denmark

Afprøvning af medicin på sjældne områder: hvad er udfordringerne. Dr. Peter Høngaard Andersen, CEO, Innovation Fund Denmark Afprøvning af medicin på sjældne områder: hvad er udfordringerne Dr. Peter Høngaard Andersen, CEO, Innovation Fund Denmark What is a Rare Disease There is no single, widely accepted definition of rare

More information

Challenges in Developing Therapeutics in Partially Responsive and Treatment Resistant Depression Where do we go from here?

Challenges in Developing Therapeutics in Partially Responsive and Treatment Resistant Depression Where do we go from here? Challenges in Developing Therapeutics in Partially Responsive and Treatment Resistant Depression Where do we go from here? Heddie Martynowicz, MS Senior Director, Global Regulatory Affairs Janssen R &

More information

<Insert Picture Here> The Evolution Of Clinical Data Warehousing

<Insert Picture Here> The Evolution Of Clinical Data Warehousing The Evolution Of Clinical Data Warehousing Srinivas Karri Principal Consultant Agenda Value of Clinical Data Clinical Data warehousing & The Big Data Challenge

More information

Alberta/Novartis Translational Research Fund Opportunity. Program Guide 2014/2015

Alberta/Novartis Translational Research Fund Opportunity. Program Guide 2014/2015 OBJECTIVES Program Guide 2014/2015 Alberta Innovates - Health Solutions (AIHS), Novartis Pharmaceuticals Canada Inc. (Novartis), and the Government of Alberta have partnered to create the Alberta/Novartis

More information

ORACLE HEALTH SCIENCES INFORM ADVANCED MOLECULAR ANALYTICS

ORACLE HEALTH SCIENCES INFORM ADVANCED MOLECULAR ANALYTICS ORACLE HEALTH SCIENCES INFORM ADVANCED MOLECULAR ANALYTICS INCORPORATE GENOMIC DATA INTO CLINICAL R&D KEY BENEFITS Enable more targeted, biomarker-driven clinical trials Improves efficiencies, compressing

More information

Testimony of Timothy Coetzee, Ph.D. Representative of a Patient Advocacy Organization President, Fast Forward LLC

Testimony of Timothy Coetzee, Ph.D. Representative of a Patient Advocacy Organization President, Fast Forward LLC Testimony of Timothy Coetzee, Ph.D. Representative of a Patient Advocacy Organization President, Fast Forward LLC Committee on Oversight and Government Reform Domestic Policy Subcommittee U.S. House of

More information

Research Agenda and Opportunities for Co-Funding

Research Agenda and Opportunities for Co-Funding Research Agenda and Opportunities for Co-Funding Joe Selby, MD, MPH, Executive Director Inter-agency Pain Research Coordinating Committee February 4, 2014 Agenda for Today Introducing PCORI 2 Funding Mechanisms

More information

Free to Breathe 2015 Research Grant To Prevent or Stop Lung Cancer Metastasis. Request for Proposals

Free to Breathe 2015 Research Grant To Prevent or Stop Lung Cancer Metastasis. Request for Proposals Free to Breathe 2015 Research Grant To Prevent or Stop Lung Cancer Metastasis Request for Proposals Award Overview Free to Breathe has a new funding opportunity solely focused on research to prevent or

More information

Practical Image Management for

Practical Image Management for Practical Image Management for Pharma Experiences and Directions. Use of Open Source Stefan Baumann, Head of Imaging Infrastructure, Novartis Agenda Introduction Drug Development, Imaging Trial Overview

More information

Gaining Ground in Translation Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health

Gaining Ground in Translation Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health Gaining Ground in Translation Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health Some Key Challenges in Biomedical Research Providing robust methods and tools for translation Conducting

More information

Global Alzheimer s Platform. Luc Truyen, ltruyen8@its.jnj.com George Vradenburg, vradenburg@aol.com Debra Lappin, debra.lappin@faegrebd.

Global Alzheimer s Platform. Luc Truyen, ltruyen8@its.jnj.com George Vradenburg, vradenburg@aol.com Debra Lappin, debra.lappin@faegrebd. Global Alzheimer s Platform 2015 Luc Truyen, ltruyen8@its.jnj.com George Vradenburg, vradenburg@aol.com Debra Lappin, debra.lappin@faegrebd.com 1 Presentation 1. Today s Reality 2. Global Momentum 3. GAP

More information

IMI2: why, what, how?

IMI2: why, what, how? IMI2: why, what, how? The Right prevention and treatment, to the right patient, at the right time Isabelle Thizon-de Gaulle VP, Strategic initiatives & Scientific relations Sanofi R&D Innovative Medicines

More information

CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis

CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis The Centre for Drug Research and Development (CDRD) and the Multiple Sclerosis Society

More information

Quality by Design Concept

Quality by Design Concept 3rd Jerusalem Conference on Quality and Pharma Sciences 6-7 June, 2012 QbD in Clinical Research - Where Can QbD Impact Clinical Research Practices? Dr. Yafit Stark Vice President, TEVA Pharmaceutical Industries,

More information

Dorothy A. Jones RN, EdD, FAAN Professor of Nursing Boston College William F. Connell SON Director, Y.L. Munn Center for Nursing Research

Dorothy A. Jones RN, EdD, FAAN Professor of Nursing Boston College William F. Connell SON Director, Y.L. Munn Center for Nursing Research Dorothy A. Jones RN, EdD, FAAN Professor of Nursing Boston College William F. Connell SON Director, Y.L. Munn Center for Nursing Research Massachusetts General Hospital Emerging trends in education and

More information

CheckWare for mental health. All psychometric tests in one solution

CheckWare for mental health. All psychometric tests in one solution CheckWare for mental health All psychometric tests in one solution Reliable, scalable and proven All psychometric tests in one solution CheckWare is made specifically for mental health care organisations

More information

Dr Alexander Henzing

Dr Alexander Henzing Horizon 2020 Health, Demographic Change & Wellbeing EU funding, research and collaboration opportunities for 2016/17 Innovate UK funding opportunities in omics, bridging health and life sciences Dr Alexander

More information

Visual Analytics to Enhance Personalized Healthcare Delivery

Visual Analytics to Enhance Personalized Healthcare Delivery Visual Analytics to Enhance Personalized Healthcare Delivery A RENCI WHITE PAPER A data-driven approach to augment clinical decision making CONTACT INFORMATION Ketan Mane, PhD kmane@renci,org 919.445.9703

More information

> Semantic Web Use Cases and Case Studies

> Semantic Web Use Cases and Case Studies > Semantic Web Use Cases and Case Studies Case Study: Applied Semantic Knowledgebase for Detection of Patients at Risk of Organ Failure through Immune Rejection Robert Stanley 1, Bruce McManus 2, Raymond

More information

MEDICAL DATA MINING. Timothy Hays, PhD. Health IT Strategy Executive Dynamics Research Corporation (DRC) December 13, 2012

MEDICAL DATA MINING. Timothy Hays, PhD. Health IT Strategy Executive Dynamics Research Corporation (DRC) December 13, 2012 MEDICAL DATA MINING Timothy Hays, PhD Health IT Strategy Executive Dynamics Research Corporation (DRC) December 13, 2012 2 Healthcare in America Is a VERY Large Domain with Enormous Opportunities for Data

More information

Organization and Job Profile

Organization and Job Profile Organization and Job Profile New Orleans, Louisiana Position: Reports to: Location: System Vice President for Research New Orleans, Louisiana CORPORATE BACKGROUND is a non-profit, academic, multi-specialty,

More information

MS IN EUROPE Overview of the

MS IN EUROPE Overview of the CHANGING THE LANDSCAPE OF MS IN EUROPE Overview of the EMSP 2015-2020 Strategic Plan The Voice of People Living with MS in Europe The European Multiple Sclerosis Platform (EMSP) exists to improve the quality

More information

Donna J. Dean, Ph.D. October 27, 2009 Brown University

Donna J. Dean, Ph.D. October 27, 2009 Brown University Building Connections with NIH Program Officers: Myths and Realities Donna J. Dean, Ph.D. October 27, 2009 Brown University Funding Agencies Federal Agencies Focused on Biomedical Research s of Health (NIH)

More information

Enabling the Health Continuum with Informatics. Jeroen Tas Healthcare Informatics.Solutions.Services

Enabling the Health Continuum with Informatics. Jeroen Tas Healthcare Informatics.Solutions.Services Enabling the Health Continuum with Informatics Jeroen Tas Healthcare Informatics.Solutions.Services The changing global healthcare landscape requires a fundamentally different informatics approach Enabling

More information

PHARMACEUTICAL BIGDATA ANALYTICS

PHARMACEUTICAL BIGDATA ANALYTICS PHARMACEUTICAL BIGDATA ANALYTICS ANDINSIGHTS December 2013 Strategic Research Insights, Inc. 2013 Sources of Big Data in rpharmaceutical and Healthcare Industry Challenges with Big Data in Pharma Oncology

More information

The NIH Roadmap: Re-Engineering the Clinical Research Enterprise

The NIH Roadmap: Re-Engineering the Clinical Research Enterprise NIH BACKGROUNDER National Institutes of Health The NIH Roadmap: Re-Engineering the Clinical Research Enterprise Clinical research is the linchpin of the nation s biomedical research enterprise. Before

More information

Accelerating Gene Therapy for Rare Genetic Diseases

Accelerating Gene Therapy for Rare Genetic Diseases Accelerating Gene Therapy for Rare Genetic Diseases P.J. Brooks, Ph.D. and Stephen C. Groft, Pharm. D. Office of Rare Diseases Research Division of Program Coordination, Planning, and Strategic Initiatives

More information

Location for Trials- Global Considerations A Pharma Perspective. Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014

Location for Trials- Global Considerations A Pharma Perspective. Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014 Location for Trials- Global Considerations A Pharma Perspective Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014 Why Choose Australia for Clinical Trials? What is he saying

More information

J D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H

J D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H J D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H PURPOSE JDRF, the world s leading non-profit organization

More information

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Maria Isaac, MASc, MD, PhD, MFPM, Psychiatrist Senior Scientific Officer Institute

More information

Accelerating Cross-Sectoral Collaboration on Data in Climate, Education and Health

Accelerating Cross-Sectoral Collaboration on Data in Climate, Education and Health Accelerating Cross-Sectoral Collaboration on Data in Climate, Education and Health A Workshop on Data Sharing and Emerging Data Collaboratives U.S. General Services Administration Building 1800 F Street,

More information

How Foundations and Non-Profits Are Using Prize Challenges to Achieve Their Missions

How Foundations and Non-Profits Are Using Prize Challenges to Achieve Their Missions EXECUTIVE WHITE PAPER How Foundations and Non-Profits Are Using Prize Challenges to Achieve Their Missions Introduction The non-profit sector (or Independent Sector/Third Sector/Voluntary Sector) plays

More information

Center for Drug & Alcohol Programs

Center for Drug & Alcohol Programs Center for Drug & Alcohol Programs Changing What s Possible... through World-Class Research Education Patient Care Outreach CDAP is Changing What s Possible Mission To combat alcoholism and drug addiction

More information

TIPPING POINT: HOSPITAL RESILIENCE IN A PERFECT STORM

TIPPING POINT: HOSPITAL RESILIENCE IN A PERFECT STORM TIPPING POINT: HOSPITAL RESILIENCE IN A PERFECT STORM Written by Using analytics to mine large datasets for insights, commonly known as Big Data, is already transforming industries ranging from consumer

More information

Morehouse School of Medicine

Morehouse School of Medicine Morehouse School of Medicine Strategic Plan March 2015 1 STRATEGIC FRAMEWORK Mission, Vision, Core Values, Goals 2 Strategic Structure Each Statement Lays the Foundation for the Next Vision Vision Goals

More information

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to

More information

A vaccine for rheumatoid arthritis

A vaccine for rheumatoid arthritis A vaccine for rheumatoid arthritis Professor Ranjeny Thomas Founder and Director of Dendright Pty Limited Head, Autoimmunity Division, Diamantina Institute, The University of Queensland About Dendright

More information

Introduction and Invitation for Public Comment

Introduction and Invitation for Public Comment 2 of 22 Introduction and Invitation for Public Comment The Patient-Centered Outcomes Research Institute (PCORI) is an independent, non-profit health research organization. Its mission is to fund research

More information

exactly. The need for efficiency in developing effective new therapeutics has never been greater.

exactly. The need for efficiency in developing effective new therapeutics has never been greater. exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,

More information

There are 2 types of clinical trials that are of interest to the. The Clinical Trials Network of the Society of Nuclear Medicine

There are 2 types of clinical trials that are of interest to the. The Clinical Trials Network of the Society of Nuclear Medicine The Clinical Trials Network of the Society of Nuclear Medicine Michael M. Graham, PhD, MD The Clinical Trials Network of the Society of Nuclear Medicine was formed to provide quality assurance of both

More information

to Advance Discovery NAS Committee on Use of Emerging Science for Allen Dearry, Ph.D., NIEHS

to Advance Discovery NAS Committee on Use of Emerging Science for Allen Dearry, Ph.D., NIEHS Integrating Environmental Health Data to Advance Discovery NAS Committee on Use of Emerging Science for Environmental Health Decisions January 10-11, 2013 Allen Dearry, Ph.D., NIEHS Outline Is there a

More information

A Biopharma/Foundation Partnering Model The Leukemia & Lymphoma Society Targets, Leads & Candidates Program

A Biopharma/Foundation Partnering Model The Leukemia & Lymphoma Society Targets, Leads & Candidates Program A Biopharma/Foundation Partnering Model The Leukemia & Lymphoma Society Targets, Leads & Candidates Program Thomas O. Daniel, MD, Celgene President Research and Early Development Louis J. DeGennaro, PhD,

More information

Transforming CliniCal Trials: The ability to aggregate and Visualize Data Efficiently to make impactful Decisions

Transforming CliniCal Trials: The ability to aggregate and Visualize Data Efficiently to make impactful Decisions : The ability to aggregate and Visualize Data Efficiently to make impactful Decisions www.eclinicalsol.com White Paper Table of Contents Maximizing Your EDC Investment... 3 Emerging Trends in Data Collection...

More information